Vicini Frank, Shah Chirag, Whitworth Pat, Walker Michael, Shi Jing
Michigan Healthcare Professionals, 21st Century Oncology, Farmington Hills, Michigan.
Department of Radiation Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio.
Lymphat Res Biol. 2018 Dec;16(6):533-537. doi: 10.1089/lrb.2017.0078. Epub 2018 Aug 22.
We reviewed serial bioimpedance measurements in order to quantify the relationship between changes in these scores and a patient's risk for developing breast cancer-related lymphedema (BCRL). From April 2010 through November 2016, 505 patients were prospectively evaluated using bioimpedance spectroscopy (BIS/L-Dex). Patients received preoperative and postoperative L-Dex measurements and were categorized based upon risk for BCRL with respect to axillary staging procedure, radiation use, taxane use, and body mass index (BMI). L-Dex change was associated with the type and number of BCRL risk factors. Both axillary lymph node dissection (ALND) and regional nodal irradiation (RNI) were associated with a greater change in L-Dex ( < 0.001), although elevated BMI was not associated. The median, maximal change in L-Dex for patients treated with ALND, RNI, and taxanes was 16.7 versus 5.2 for ALND alone and 3.7 for sentinel lymph node biopsy (SLNB) alone ( = 0.016). In a model using all four risk factors to predict the maximal change in L-Dex, ALND and RNI remained significantly associated with maximum change ( < 0.05). The time required to reach maximal change in L-Dex was shorter in patients treated with ALND or RNI (the time for 25% of patients achieving an L-Dex ≥7 was 4.3 months for ALND, RNI, and taxanes patients versus 30.8 months for SLNB-alone patients). Risk factors for development of BCRL were associated with both the magnitude and timing of change in L-Dex scores. These findings demonstrate the utility of serial L-Dex measurements in providing an objective assessment of a patient's lymphedema status and the value of L-Dex serial measurements to assist in monitoring patients for the development of BCRL. This supports the clinical utilization of serial L-Dex scores to follow patients at risk for BCRL.
我们回顾了系列生物阻抗测量结果,以量化这些评分变化与患者发生乳腺癌相关淋巴水肿(BCRL)风险之间的关系。从2010年4月至2016年11月,采用生物阻抗光谱法(BIS/L-Dex)对505例患者进行了前瞻性评估。患者接受术前和术后L-Dex测量,并根据腋窝分期手术、放疗使用、紫杉烷使用和体重指数(BMI)对BCRL风险进行分类。L-Dex变化与BCRL风险因素的类型和数量相关。腋窝淋巴结清扫术(ALND)和区域淋巴结照射(RNI)均与L-Dex的更大变化相关(<0.001),尽管BMI升高与之无关。接受ALND、RNI和紫杉烷治疗的患者L-Dex的中位数、最大变化为16.7,而单纯ALND为5.2,单纯前哨淋巴结活检(SLNB)为3.7(=0.016)。在使用所有四个风险因素预测L-Dex最大变化的模型中,ALND和RNI仍与最大变化显著相关(<0.05)。接受ALND或RNI治疗的患者达到L-Dex最大变化所需的时间更短(25%的患者L-Dex≥7的时间,ALND、RNI和紫杉烷治疗的患者为4.3个月,而单纯SLNB患者为30.8个月)。BCRL发生的风险因素与L-Dex评分变化的幅度和时间均相关。这些发现证明了系列L-Dex测量在客观评估患者淋巴水肿状态方面的实用性,以及L-Dex系列测量在协助监测患者BCRL发生方面的价值。这支持了系列L-Dex评分在临床用于随访BCRL风险患者。